Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma.

Approximately 15% of the Korean patients treated with bortezomib experienced severe CVAEs. Thus, patients, especially those with identified risk factors, should be closely monitored for CVAE symptoms during bortezomib treatment.